HIV-1 Protein Tat1–72 Impairs Neuronal Dendrites via Activation of PP1 and Regulation of the CREB/BDNF Pathway
- 150 Downloads
Despite the success of combined antiretroviral therapy in recent years, the prevalence of human immunodeficiency virus (HIV)-associated neurocognitive disorders in people living with HIV-1 is increasing, significantly reducing the health-related quality of their lives. Although neurons cannot be infected by HIV-1, shed viral proteins such as transactivator of transcription (Tat) can cause dendritic damage. However, the detailed molecular mechanism of Tat-induced neuronal impairment remains unknown. In this study, we first showed that recombinant Tat (1–72 aa) induced neurotoxicity in primary cultured mouse neurons. Second, exposure to Tat1–72 was shown to reduce the length and number of dendrites in cultured neurons. Third, Tat1–72 (0–6 h) modulates protein phosphatase 1 (PP1) expression and enhances its activity by decreasing the phosphorylation level of PP1 at Thr320. Finally, Tat1–72 (24 h) downregulates CREB activity and CREB-mediated gene (BDNF, c-fos, Egr-1) expression. Together, these findings suggest that Tat1–72 might impair cognitive function by regulating the activity of PP1 and the CREB/BDNF pathway.
KeywordsRecombinant tat HIV-associated neurocognitive disorders (HAND) Dendrite impairment Protein phosphatase 1 (PP1) CREB/BDNF
This work was supported by Grants from the National Natural Science Foundation of China (81571987).
YL and CL conceived the experiments. YL, DYZ, JBF, ZL, and YH carried out the experiments. YL and DYZ analyzed the data. YL, CL, and XHK wrote the paper. All authors read and approved the final manuscript.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
Animal and Human Rights Statement
The whole study was approved by the Administrative Committee on Animal Welfare of School of Medicine, Nankai University, China (Laboratory Animal Care and Use Committee Authorization, permit number SYXK-2014-0003). All institutional and national guidelines for the care and use of laboratory animals were followed.
- Deyer SM, Rodriguez M, Lapierre J, Costinl BN, El-Hage N (2015) Differing roles of autophagy in HIV-associated neurocognitive impairment and encephalitis with implications for morphine co-exposure. Front Microbiol 6:653Google Scholar
- Fitting S, Xu R, Bull C, Buch SK, El-Hage N, Nath A, Knapp PE, Hauser KF (2010) Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 177:1397–1410CrossRefPubMedPubMedCentralGoogle Scholar
- Fitting S, Ignatowska-Jankowska BM, Bull C, Skoff RP, Lichtman AH, Wise LE, Fox MA, Su J, Medina AE, Krahe TE, Knapp PE, Guido W, Hauser KF (2013) Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. Biol Psychiatry 73:443–453CrossRefPubMedGoogle Scholar
- Robertson K, Bayon C, Molina JM, McNamara P, Resch C, Munoz-Moreno JA, Kulasegaram R, Schewe K, Burgos-Ramirez A, De Alvaro C, Cabrero E, Guion M, Norton M, van Wyk J (2014) Screening for neurocognitive impairment, depression, and anxiety in HIV-infected patients in Western Europe and Canada. AIDS Care 26:1555–1561CrossRefPubMedPubMedCentralGoogle Scholar
- Zhou HX, Li XY, Li FY, Liu C, Liang ZP, Liu S, Zhang B, Wang TY, Chu TC, Lu L, Ning GZ, Kong XH, Feng SQ (2014) Targeting RPTPsigma with lentiviral shRNA promotes neurites outgrowth of cortical neurons and improves functional recovery in a rat spinal cord contusion model. Brain Res 1586:46–63CrossRefPubMedGoogle Scholar